Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Van Cleef Asset Management Inc

Van Cleef Asset Management Inc lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,215 shares of the biopharmaceutical company’s stock after selling 200 shares during the period. Van Cleef Asset Management Inc’s holdings in Gilead Sciences were worth $828,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. Altfest L J & Co. Inc. acquired a new stake in Gilead Sciences in the fourth quarter valued at $210,000. Federated Hermes Inc. lifted its position in shares of Gilead Sciences by 4.9% in the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after acquiring an additional 175,925 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $74,000. Abundance Wealth Counselors purchased a new stake in shares of Gilead Sciences in the third quarter valued at $1,881,000. Finally, HTLF Bank purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $253,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 2.7 %

Shares of GILD stock traded down $1.81 during trading hours on Thursday, reaching $65.27. The company had a trading volume of 15,163,484 shares, compared to its average volume of 7,415,576. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. Gilead Sciences, Inc. has a twelve month low of $65.09 and a twelve month high of $87.86. The company has a market capitalization of $81.27 billion, a P/E ratio of 14.98, a price-to-earnings-growth ratio of 0.96 and a beta of 0.19. The stock’s fifty day simple moving average is $71.56 and its 200 day simple moving average is $76.39.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same quarter last year, the firm earned $1.37 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 5.24 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.72%. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on GILD shares. Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Cantor Fitzgerald reduced their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Oppenheimer reiterated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Royal Bank of Canada reduced their target price on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 14th. Finally, Wells Fargo & Company dropped their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $84.57.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.